Report #2888679

Received Mar 12, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: —
Recovered: Recovered
Vaccinated: Mar 6, 2026
Onset: Mar 7, 2026
Days to onset: 1
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	UNK	—

Symptoms (3)

ChillsHeadacheMyalgia

Symptom narrative

Headache; Chills; Myalgia; This non-serious case was reported by a consumer and described the occurrence of headache in a 60-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Concurrent medical conditions included hyperlipidemia. Concomitant products included rosuvastatin calcium (Crestor). On 06-MAR-2026, the patient received the 2nd dose of Shingrix. On 07-MAR-2026, 1 days after receiving Shingrix, the patient experienced headache (Verbatim: Headache), chills (Verbatim: Chills) and myalgia (Verbatim: Myalgia). On 07-MAR-2026, the outcome of the headache, chills and myalgia were resolved. It was unknown if the reporter considered the headache, chills and myalgia to be related to Shingrix. It was unknown if the company considered the headache, chills and myalgia to be related to Shingrix. Additional Information: GSK Receipt Date: 08-MAR-2026 The batch number was not provided, and we are unable to contact the reporter.

Current illness

Hyperlipidemia

Other medications

CRESTOR